1. INTRODUCTION {#sec1-1}
===============

Acinetobacter baumannii is a non fermentative Gram-negative coccobacillus that is emerged as opportunistic nosocomial pathogen. A variety of human infections caused by Acinetobacter species have been reviewed including pneumonia (most often related to endotracheal tubes or tracheostomies), endocarditis, meningitis, skin and wound infections, peritonitis (in patients receiving peritoneal dialysis) and urinary tract infections ([@ref1]).

Multidrug-resistant (MDR) A. baumannii is increasingly held responsible for nosocomial infections ([@ref2]) and plays a significant role in colonization and infection of hospitalized patients and can transmit from patient to patient with direct and indirect contact. The main risk factors of Acinetobacter baumannii bacteremia are invasive procedures such as central venous catheterization, mechanical ventilation and surgical procedures. Other risks include previous antimicrobial treatment, number of antimicrobial agents prescribed, treatment with carbapenems, cephalosporins or aminoglycosides, prolonged hospital stay, previous ICU stay, enteral nutrition ([@ref3]).

A. baumannii can develop multiple antimicrobial resistance extremely quickly what is in contrast to other clinical bacteria, which require greater time to acquire resistance, usually in response to therapeutic strategies. General mechanisms of resistance are enzyme-mediated resistance, genetic adaptation, efflux pump and changes in the structure of the outer membrane ([@ref4]). The ability to chronically colonize patients and cause outbreaks which are usually hard to eradicate poses significant challenges to infection control and increases healthcare costs ([@ref5]). The selection and spread of resistant bacteria in hospitals is the biggest threat to patient safety.

The consequences of inappropriate antimicrobial treatment are increasing mortality and morbidity, adverse effects, prolonged hospital stay, secondary infection, the emergence of resistant microorganisms and increase of health care costs. Mortality, misuse of antimicrobials and microbial resistance are closely related ([@ref6]).

Effective supervision is cornerstone of national and international efforts to control antimicrobial resistance. Monitoring the use of antibiotics, the occurrence and spread of resistant strains of bacteria provides the information and tools that are needed to promote appropriate use of antibiotics at all levels, from local to global.

In Bosnia and Herzegovina there is no established antimicrobial resistance surveillance system and there is no monitoring the influence of antibiotic consumption on development of bacterial resistance. The aim of this study was to examine the impact of antibiotic consumption on development of antimicrobial resistance in Acinetobacter baumannii.

2. MATERIALS AND METHODS {#sec1-2}
========================

The study was conducted in University Clinical Center of Sarajevo, isolates of Acinetobacter baumannii in period from July 1^st^ 2009 to December 31^st^ 2012. Isolates were detected from different clinical samples including urine, wound swab, blood, bronchial aspirate and other samples which were collected from patients situated on various hospital wards. Clinical isolates belonged to one per patient in a given period of time.

Identification of *Acinetobacter baumannii* isolates was done on the basis of morphological, cultural and biochemical characteristics. In addition, automated VITEK 2 Compact system (bioMérieux, Marcy l'Étoile, France) was used to aid in confirmation of the A. baumannii isolates ([@ref8]).

Antimicrobial resistance profile was determined by automated VITEK 2 Compact system (bioMérieux, Marcy l'Étoile, France) for: ceftriaxone, ceftazidime, cefotaxim, amikacin, gentamycin, imipenem, meropenem, ciprofloxacin, levofloxacin, trimetoprim-sulfametoksazol, cefepime, piperacilin/tazobactam, colistin, tobramycin. Results were interpreted according to CLSI breakpoints ([@ref9]).

Consumption of above mentioned antibiotics was given in standard units (pill, capsule, or ampoule) and analyzed according to the recommendations of the ESAC-Net and current ATC classification. To better demonstrate the statistical data analysis, the research period is divided into 14 quarterly periods, respectively.

Descriptive statistics was applied. Results were given as total numbers, proportions, means±SD, and medians with ranges, where appropriate.

3. RESULTS {#sec1-3}
==========

Over the study period, a total consumption of tested antimicrobials was 865,904 pieces, of which quinolones 285601 (33%), cephalosporin's 3^rd^ and 4^th^ generation with 208765 (24,1%), aminoglycosides 103227 (11,9%), carbapenems 107092 (12,36%). Consumption of particular antibiotics is shown in [Table 1](#T1){ref-type="table"}.

###### 

Antibiotic consumption on Quarter (Qtr) level
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Between 2009 and 2012, consumption of all antimicrobials increased by 50% (from 65835 in 2009 to 98272 in 2012). The most commonly used antibiotic was ciprofloxacin -- 275316 pieces (31,8%), then trimethoprim/sulfamethoxazol 155882 (18%), while the lowest consumption had colistin with 777 (0,08%) pieces, cefotaxime 2155 (0,24%) and piperacillin/tazobactam 4560 (0,52%) pieces, respectively. Highest consumption was during 11^th^ quarter (Qtr), while the lowest was during 7^th^ quarter ([Table 1](#T1){ref-type="table"}).

Over the studied period a total of 1977 isolates of Acinetobacter baumannii were analyzed. Antibiotic resistance pattern was shown in [Table 2](#T2){ref-type="table"} and Graph 1. The highest rate of resistance was to the 3^rd^ generation of cephalosporin´s (\~96%) and ciprofloxacin (91,87%), while there was no resistance to colistin. Resistance to imipenem and meropenem increased from 27% and 34% in 1^st^ Qtr to 80% in 11^th^ Qtr. For piperacillin/tazobactam the increase was from 33% in 1^st^ to 88% in 11^th^ Qtr. Resistance to ciprofloxacin increased from 80% to 100% in 14^th^ quarter. Resistance to amikacin increased from 48,53% in 3^rd^ Qtr to 86% in 11^th^ Qtr, while there was an increase of resistance to tobramycin from 8,5% in 3^rd^ Qtr to 16% in 13^th^ Otr. There was slightly derease of resistance to gentamicin from 85,9% in 3^rd^ Qtr to 64% in 13^th^ Qtr respectively ([Table 2](#T2){ref-type="table"}, [Figure 1](#F1){ref-type="fig"} and 2).

###### 

An overall resistance of Acinetbacter baumannii to antimicrobials during the observed period
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![Percentage of A.baumannii isolates resistant to particular antibiotics in the observed period.](MSM-28-449-g003){#F1}

Pearson's correlation test showed no significant correlation between the resistance of Acinetobacter baumannii and consumption of antimicrobials, except with gentamicin. The positive, statistically significant correlation was demonstrated between gentamicin consumption and emerging of resistance (p = 0.023) ([Table 3](#T3){ref-type="table"}).

###### 

Correlation between the incidence of resistant A.baumannii forms and consumption of certain antibiotics in the examined period
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4. DISCUSSION {#sec1-4}
=============

Our results showed that Acinetobacter baumannii is among the most resistant bacteria and antimicrobial ssusceptibility testing pointed that it is a multidrug-resistant bacteria. This was confirmed and similar by results of authors from Italy ([@ref10]), Slovakia ([@ref11]), Greece ([@ref12]).

Resistance to imipenem and meropenem increased from 27% and 34% in 1^st^ quarter to 80% in 11^th^ Qtr. According to information from the Croatian Committee for Antibiotic Resistance Surveillance of the CAMS, resistance of clinical isolates of ABC to carbapenems in Croatia from 2006 to 2011 ranged from 2% for imipenem and 11% for meropenem in 2006, to 64% in 2011 ([@ref13]), and in larger hospitals is 90% ([@ref13],[@ref14]). The resistance of Acinetobacter baumannii to carbapenems, mostly to imipenem, has been the topic of various papers, and the published data on the resistance rates to imipenem have reported from 21% up to 100% of the tested isolates of A. baumannii ([@ref15], [@ref16], [@ref17]). Among the European countries the resistance rates to carbapenems are highest in the countries in southern Europe, such as Greece and Croatia ([@ref14], [@ref19]).

Over the study period we observed increased consumption of carbapenem antibiotics what resulted in increasing resistance on carbapenems in Acinetobacter baumannii. Highest consumption of imipenem and meropenem was in 11^th^ quarter and in the same period the highest resistance to carbapenems was observed, but there was no correlation between resistance and consumption by Pearson correlation test. Carbapenem justified use in ESBL isolates (Eng. Extended spectrum β-lactamase; ESBL) reflected to the resistance of nonfermentative bacteria primarily A. baumannii ([@ref18]). If we compare the resistance of imipenem and meropenem we can find that through all 14 quarters greater resistance was to meropenem. This is similar to the data of Committee for Antibiotic Resistance Surveillance in the Republic of Croatia for the period 2002 - 2008, where the difference in sensitivity within the carbapenem antibiotics group was observed and almost all microbiological laboratories had a higher percentage of resistant isolates of A. baumannii to meropenem over imipenem ([@ref13]).

Average resistance to the 3^rd^ generation of cephalosporins is \~ 95%, 97% to ciprofloxacin and to cefepime 76%. Medic et al. found that the resistance to cephalosporins third and fourth generations as well as ciprofloxacin was greater than 93% ([@ref19]). Acinetobacter baumannii isolates are often susceptible only to colistin or tigecycline. Over the study period there was no resistance to colistin. SENTRY Antimicrobial Surveillance from 2001 to 2011, which includes different centers in USA, Europe, South America and Asia, showed that colistin resistance was on low level (0.9%--3.3%) ([@ref20], [@ref21]). According to data collected by the European Regional Branch of study monitoring resistance in 2011, followed by the antimicrobial resistance in 21 countries of Europe including Belgium, Bulgaria, Croatia, Czech Republic, France, Germany, etc, Acinetobacter was less susceptible to all antibiotics except colistin. In the European component of the Regional Resistance Surveillance study for 2011, a total of 21 countries were monitored for antimicrobial resistance patterns including Belgium, Bulgaria, Croatia, Czech Republic, France, Germany, Greece, Ireland, Italy, Poland, Portugal, Russia, Slovenia, Spain, Sweden, United Kingdom etc. *Acinetobacter* was generally less susceptible, except against COL (99.2--99.6% S) and TIG (95.0% inhibited at ≤2 µg/mL) ([@ref22]).

Application of Pearson's correlation to the resistance of Acinetobacter baumannii compared to consumption of certain antibiotics not found a significant correlation between these two variables in all tested antibiotics, except with to gentamicin where a positive, statistically significant correlation (p = 0.023) was proven. Pearson´s correlation test showed no significant correlation between the resistance of Acinetobacter baumannii and consumption of antimicrobials, except with gentamicin. The positive, statistically significant correlation was demonstrated between gentamicin consumption and emerging of resistance (p = 0.023). There are a lot of studies about relationship between consumption of antimicrobial agents and developing of resistance. Sedláková et al. found a positive correlation between aminoglycoside consumption and resistance to gentamicin in Escherichia colli and Klebsiella pneumonia ([@ref23]). H Jin et al. found that gentamicin usage was significantly correlated with resistance in Acinetobacter baumannii to this drug ([@ref24]).

5. CONCLUSION {#sec1-5}
=============

Increase in the antimicrobial use in University Clinical Center of Sarajevo was followed with an increase in resistance of Acinetobacter baumannii isolates. The fastest development of resistance has been to carbapenems, while there was no resistance to colistin. There was a positive correlation between the development of resistance and consumption of gentamicin. Monitoring of antibiotic resistance and consumption is of a great importance in order to reduce the emergence and spread of antimicrobial resistant organisms in the health care settings.
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